Japan's Daiichi Sankyo to make cutting-edge cancer treatments in China

Company behind breast cancer drug Enhertu to spend $152m on new production facility

Enhertu from Daiichi Sankyo and AstraZeneca has been approved in China to treat some forms of breast cancer. (Daiichi Sankyo)

TAITO KUROSE, Nikkei staff writer

November 30, 2024 03:38 JST

TOKYO -- Japanese drugmaker Daiichi Sankyo said Friday it plans to make cancer treatments in China in response to growing demand there.

The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use antibodies to deliver targeted attacks on cancer cells. The breast cancer drug Enhertu from Daiichi Sankyo and AstraZeneca is a type of ADC.